CRDL (Cardiol Therapeutics Inc.) היקף יתרות המזומנים של החברה

The strengthening position of Cardiol Therapeutics (CRDL) is based on patents for treating myocarditis with ultra-pure cannabidiol. Geographic coverage in Europe and the US hedges regulatory risks, although cash flows remain volatile until testing is completed. The amount of operating cash reflects the market consensus on liquidity, where the current value equals 0.02, which determines the issuer's current financial reserve.
פילוחים אנליטיים של חברת Cardiol Therapeutics

Clinical trials of anti-inflammatory agents by Cardiol Therapeutics (CRDL) require significant expenditures, which temporarily limits operational efficiency during the pre-profit stage. By analyzing the size of the cash reserve, the investor assesses the total liquidity balance to monitor the burn rate and prevent cash flow gaps, which is critical for maintaining the company's capitalization until the development phases are completed.